

Illana Gozes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2296698/illana-gozes-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

262
papers

14,664
citations

57
h-index

111
g-index

305
ext. papers

16,407
ext. citations

5
avg, IF

6.21
L-index

#	Paper	IF	Citations
262	STOP Codon Mutations at Sites of Natural Caspase Cleavage Are Implicated in Autism and Alzheimer's Disease: The Case of ADNP.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 867442	5.7	1
261	Outdoor PM concentration and rate of change in COVID-19 infection in provincial capital cities in China. <i>Scientific Reports</i> , 2021 , 11, 23206	4.9	2
260	Therapeutic Potential of Vasoactive Intestinal Peptide and its Derivative Stearyl-Norleucine-VIP in Inflammation-Induced Osteolysis. <i>Frontiers in Pharmacology</i> , 2021 , 12, 638128	5.6	1
259	Introducing ADNP and SIRT1 as new partners regulating microtubules and histone methylation. <i>Molecular Psychiatry</i> , 2021 ,	15.1	5
258	A Different Outlook at Psychiatric and Neurological Diseases: Brain Somatic Mutations Are Implicated in Schizophrenia. <i>Biological Psychiatry</i> , 2021 , 90, 6-8	7.9	2
257	Discovery of autism/intellectual disability somatic mutations in Alzheimer's brains: mutated ADNP cytoskeletal impairments and repair as a case study. <i>Molecular Psychiatry</i> , 2021 , 26, 1619-1633	15.1	24
256	Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy. <i>Progress in Molecular Biology and Translational Science</i> , 2021 , 177, 65-90	4	2
255	Putative Blood Somatic Mutations in Post-Traumatic Stress Disorder-Symptomatic Soldiers: High Impact of Cytoskeletal and Inflammatory Proteins. <i>Journal of Alzheimer's Disease</i> , 2021 , 79, 1723-1734	4.3	3
254	Novel ADNP Syndrome Mice Reveal Dramatic Sex-Specific Peripheral Gene Expression With Brain Synaptic and Tau Pathologies. <i>Biological Psychiatry</i> , 2021 ,	7.9	2
253	Immune-modulatory Properties of the Octapeptide NAP in Infected Mice Suffering from Acute Enterocolitis. <i>Microorganisms</i> , 2020 , 8,	4.9	7
252	Microbiota changes associated with ADNP deficiencies: rapid indicators for NAP (CP201) treatment of the ADNP syndrome and beyond. <i>Journal of Neural Transmission</i> , 2020 , 127, 251-263	4.3	6
251	Neurotrophic Action of VIP 2020 , 383-408		3
250	Analysis of HCRTR2, GNB3, and ADH4 Gene Polymorphisms in a Southeastern European Caucasian Cluster Headache Population. <i>Journal of Molecular Neuroscience</i> , 2020 , 70, 467-474	3.3	7
249	Tauopathy in the young autistic brain: novel biomarker and therapeutic target. <i>Translational Psychiatry</i> , 2020 , 10, 228	8.6	18
248	The National Autism Database of Israel: a Resource for Studying Autism Risk Factors, Biomarkers, Outcome Measures, and Treatment Efficacy. <i>Journal of Molecular Neuroscience</i> , 2020 , 70, 1303-1312	3.3	6
247	Sex-and Region-Dependent Expression of the Autism-Linked ADNP Correlates with Social- and Speech-Related Genes in the Canary Brain. <i>Journal of Molecular Neuroscience</i> , 2020 , 70, 1671-1683	3.3	2
246	Single Cell ADNP Predictive of Human Muscle Disorders: Mouse Knockdown Results in Muscle Wasting. <i>Cells</i> , 2020 , 9,	7.9	1

245	Age and Sex-Dependent ADNP Regulation of Muscle Gene Expression Is Correlated with Motor Behavior: Possible Feedback Mechanism with PACAP. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
244	The ADNP Syndrome and CP201 (NAP) Potential and Hope. <i>Frontiers in Neurology</i> , 2020 , 11, 608444	4.1	5
243	Activity-dependent neuroprotective protein (ADNP)/NAP (CP201): Autism, schizophrenia, and Alzheimer's disease 2020 , 3-20		1
242	The autism-mutated ADNP plays a key role in stress response. <i>Translational Psychiatry</i> , 2019 , 9, 235	8.6	15
241	The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse. <i>Translational Psychiatry</i> , 2019 , 9, 2	8.6	19
240	Cellular and animal models of skin alterations in the autism-related ADNP syndrome. <i>Scientific Reports</i> , 2019 , 9, 736	4.9	17
239	Cancer-associated stroke: Pathophysiology, detection and management (Review). <i>International Journal of Oncology</i> , 2019 , 54, 779-796	4.4	57
238	Atypical Auditory Brainstem Response and Protein Expression Aberrations Related to ASD and Hearing Loss in the Adnp Haploinsufficient Mouse Brain. <i>Neurochemical Research</i> , 2019 , 44, 1494-1507	4.6	6
237	Developmental Phenotype of the Rare Case of DJ Caused by a Unique ADNP Gene De Novo Mutation. <i>Journal of Molecular Neuroscience</i> , 2019 , 68, 321-330	3.3	9
236	Single-cell analysis of cytoskeleton dynamics: From isoelectric focusing to live cell imaging and RNA-seq. <i>Journal of Neuroscience Methods</i> , 2019 , 323, 119-124	3	2
235	NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies. <i>PLoS ONE</i> , 2019 , 14, e0213666	3.7	21
234	Reduction of aluminum ion neurotoxicity through a small peptide application - NAP treatment of Alzheimer's disease. <i>Journal of Food and Drug Analysis</i> , 2019 , 27, 551-564	7	13
233	The blood-brain barrier and beyond: Nano-based neuropharmacology and the role of extracellular matrix. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019 , 17, 359-379	6	30
232	VIP/PACAP-Based Drug Development: The ADNP/NAP-Derived Mirror Peptides SKIP and D-SKIP Exhibit Distinctive and Effects. <i>Frontiers in Cellular Neuroscience</i> , 2019 , 13, 589	6.1	1
231	Activity-dependent neuroprotective protein (ADNP) is an alcohol-responsive gene and negative regulator of alcohol consumption in female mice. <i>Neuropsychopharmacology</i> , 2019 , 44, 415-424	8.7	8
230	ADNP differentially interact with genes/proteins in correlation with aging: a novel marker for muscle aging. <i>GeroScience</i> , 2019 , 41, 321-340	8.9	3
229	Does SCFD1 rs10139154 Polymorphism Decrease Alzheimer's Disease Risk?. <i>Journal of Molecular Neuroscience</i> , 2019 , 69, 343-350	3.3	10
228	A Novel Microtubule-Tau Association Enhancer and Neuroprotective Drug Candidate: Ac-SKIP. <i>Frontiers in Cellular Neuroscience</i> , 2019 , 13, 435	6.1	5

227	Clinical Presentation of a Complex Neurodevelopmental Disorder Caused by Mutations in ADNP. <i>Biological Psychiatry</i> , 2019 , 85, 287-297	7.9	55
226	The octapeptide NAP alleviates intestinal and extra-intestinal anti-inflammatory sequelae of acute experimental colitis. <i>Peptides</i> , 2018 , 101, 1-9	3.8	23
225	ADNP, a Microtubule Interacting Protein, Provides Neuroprotection Through End Binding Proteins and Tau: An Amplifier Effect. <i>Frontiers in Molecular Neuroscience</i> , 2018 , 11, 151	6.1	12
224	Anti-inflammatory Effects of the Octapeptide NAP in Human Microbiota-Associated Mice Suffering from Subacute Ileitis. <i>European Journal of Microbiology and Immunology</i> , 2018 , 8, 34-40	4.6	11
223	Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4956-4969	15.9	38
222	NAP Protects against Tau Hyperphosphorylation Through GSK3. <i>Current Pharmaceutical Design</i> , 2018 , 24, 3868-3877	3.3	10
221	ADNP Regulates Cognition: A Multitasking Protein. <i>Frontiers in Neuroscience</i> , 2018 , 12, 873	5.1	7
220	ADNP Plays a Key Role in Autophagy: From Autism to Schizophrenia and Alzheimer's Disease. <i>BioEssays</i> , 2017 , 39, 1700054	4.1	29
219	Specific protein biomarker patterns for Alzheimer's disease: improved diagnostics in progress. <i>EPMA Journal</i> , 2017 , 8, 255-259	8.8	9
218	Sexual divergence in activity-dependent neuroprotective protein impacting autism, schizophrenia, and Alzheimer's disease. <i>Journal of Neuroscience Research</i> , 2017 , 95, 652-660	4.4	8
217	The Eight and a Half Year Journey of Undiagnosed AD: Gene Sequencing and Funding of Advanced Genetic Testing Has Led to Hope and New Beginnings. <i>Frontiers in Endocrinology</i> , 2017 , 8, 107	5.7	22
216	The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP. <i>Biological Chemistry</i> , 2016 , 397, 177-84	4.5	12
215	Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2016 , 58, 145-52	3.3	9
214	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016 , 12, 1-222	10.2	3838
213	D-SAL and NAP: Two Peptides Sharing a SIP Domain. <i>Journal of Molecular Neuroscience</i> , 2016 , 59, 220-313	3.3	10
212	Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2016 , 50, 249-60	4.3	39
211	PACAP, VIP, and ADNP: Autism and Schizophrenia. <i>Current Topics in Neurotoxicity</i> , 2016 , 781-792		
210	Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy. <i>Science Translational Medicine</i> , 2016 , 8, 370ra181	17.5	22

209	ADNP/ADNP2 expression in oligodendrocytes: implication for myelin-related neurodevelopment. <i>Journal of Molecular Neuroscience</i> , 2015 , 57, 304-13	3.3	10
208	Anti-Inflammatory Properties of NAP in Acute Toxoplasma Gondii-Induced Ileitis in Mice. <i>European Journal of Microbiology and Immunology</i> , 2015 , 5, 210-20	4.6	11
207	Activity-dependent neuroprotective protein (ADNP): a case study for highly conserved chordata-specific genes shaping the brain and mutated in cancer. <i>Journal of Alzheimer's Disease</i> , 2015 , 45, 57-73	4.3	26
206	Activity-dependent neuroprotective protein (ADNP): from autism to Alzheimer's disease. <i>SpringerPlus</i> , 2015 , 4, L37		4
205	Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model. <i>Scientific Reports</i> , 2015 , 5, 16300	4.9	25
204	ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration. <i>Frontiers in Aging Neuroscience</i> , 2015 , 7, 205	5.3	13
203	ADNP: A major autism mutated gene is differentially distributed (age and gender) in the songbird brain. <i>Peptides</i> , 2015 , 72, 75-9	3.8	6
202	NAP alpha-aminoisobutyric acid (IsoNAP). <i>Journal of Molecular Neuroscience</i> , 2014 , 52, 1-9	3.3	24
201	Study of NAP adsorption and assembly on the surface of HOPG. <i>Peptides</i> , 2014 , 62, 55-8	3.8	4
200	Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davunetide). <i>Journal of Alzheimer's Disease</i> , 2014 , 40 Suppl 1, S23-36	4.3	21
199	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology</i> , 2014 , 13, 676-85	24.1	197
198	P4-274: ACTIVITY-DEPENDENT NEUROPROTECTIVE PROTEIN (ADNP): MARKING ALZHEIMER'S DISEASE AND SCHIZOPHRENIA 2014 , 10, P884-P885		
197	Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of Tau mutation. <i>PLoS ONE</i> , 2014 , 9, e87383	3.7	36
196	New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia. <i>Autophagy</i> , 2014 , 10, 2324-32	10.2	51
195	Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing β synuclein. <i>Pharmacology Research and Perspectives</i> , 2014 , 2, e00065	3.1	31
194	Davunetide: Peptide therapeutic in neurological disorders. <i>Current Medicinal Chemistry</i> , 2014 , 21, 2591-84.3	4.3	34
193	NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. <i>Neurobiology of Disease</i> , 2013 , 56, 79-94	7.5	79
192	Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP). <i>Neuropeptides</i> , 2013 , 47, 489-95	3.3	32

191	Tau Pathology: A Selected View on the Current Status. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2013 , 69-92	0.4	
190	Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. <i>British Journal of Pharmacology</i> , 2012 , 166, 4-17	8.6	306
189	D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy. <i>Journal of Molecular Neuroscience</i> , 2012 , 48, 597-602	3.3	16
188	The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. <i>PLoS ONE</i> , 2012 , 7, e51458	3.7	58
187	Tau and caspase 3 as targets for neuroprotection. <i>International Journal of Alzheimer's Disease</i> , 2012 , 2012, 493670	3.7	29
186	Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. <i>Neuropsychiatric Disease and Treatment</i> , 2012 , 8, 85-93	3.1	27
185	Neuropeptide GPCRs in neuroendocrinology: the case of activity-dependent neuroprotective protein (ADNP). <i>Frontiers in Endocrinology</i> , 2012 , 3, 134	5.7	1
184	Novel evolutionary-conserved role for the activity-dependent neuroprotective protein (ADNP) family that is important for erythropoiesis. <i>Journal of Biological Chemistry</i> , 2012 , 287, 40173-85	5.4	31
183	A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. <i>Molecular and Cellular Neurosciences</i> , 2011 , 46, 597-606	4.8	54
182	Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate. <i>Peptides</i> , 2011 , 32, 428-31	3.8	21
181	Ameliorative effect of NAP on laser-induced retinal damage. <i>Acta Ophthalmologica</i> , 2011 , 89, e126-31	3.7	13
180	Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. <i>European Neuropsychopharmacology</i> , 2011 , 21, 355-61	1.2	49
179	Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). <i>Current Pharmaceutical Design</i> , 2011 , 17, 3413-7	3.3	37
178	Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. <i>Current Pharmaceutical Design</i> , 2011 , 17, 2603-12	3.3	31
177	Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. <i>Neurobiology of Disease</i> , 2011 , 44, 327-39	7.5	39
176	NAP (davunetide) provides functional and structural neuroprotection. <i>Current Pharmaceutical Design</i> , 2011 , 17, 1040-4	3.3	47
175	The effects of vascular intrauterine growth retardation on cortical astrocytes. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2010 , 23, 595-600	2	19
174	Chapter 20: Davunetide (NAP) Pharmacology: Neuroprotection and Tau. <i>RSC Drug Discovery Series</i> , 2010 , 108-128	0.6	7

173	NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia. <i>Peptides</i> , 2010 , 31, 1368-73	3.8	49
172	Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice. <i>EPMA Journal</i> , 2010 , 1, 305-16	8.8	6
171	Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. <i>Journal of Molecular Neuroscience</i> , 2010 , 41, 114-20	3.3	27
170	3R tau expression modifies behavior in transgenic mice. <i>Journal of Neuroscience Research</i> , 2010 , 88, 2727-35	4.3	6
169	Addressing Alzheimer's disease tangles: from NAP to AL-108. <i>Current Alzheimer Research</i> , 2009 , 6, 455-60	6.0	78
168	NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. <i>Neurobiology of Disease</i> , 2009 , 34, 381-8	7.5	103
167	NAP protects against cytochrome c release: inhibition of the initiation of apoptosis. <i>European Journal of Pharmacology</i> , 2009 , 618, 9-14	5.3	29
166	NAP protects against cyanide-related microtubule destruction. <i>Journal of Neural Transmission</i> , 2009 , 116, 1411-6	4.3	13
165	A novel method for analyzing mitochondrial movement: inhibition by paclitaxel in a pheochromocytoma cell model. <i>Journal of Molecular Neuroscience</i> , 2009 , 37, 254-62	3.3	18
164	Neuroprotective protein and carboxypeptidase E. <i>Journal of Molecular Neuroscience</i> , 2009 , 39, 1-8	3.3	16
163	Young Investigator Award: Derek B. Oien (Supervisor: Jakob Moskovitz), University of Kansas. <i>Journal of Molecular Neuroscience</i> , 2009 , 39, 321-322	3.3	
162	PolyADP-ribosylation is required for long-term memory formation in mammals. <i>Journal of Neurochemistry</i> , 2009 , 111, 72-9	6	57
161	The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. <i>Journal of Neurochemistry</i> , 2009 , 111, 1252-63	6	25
160	Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress. <i>Journal of Neurochemistry</i> , 2008 , 105, 537-45	6	28
159	NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42). <i>BMC Neuroscience</i> , 2008 , 9 Suppl 3, S3	3.2	46
158	Antibody Production: Activity-Dependent Neuroprotective Protein (ADNP) as an Example. <i>Neuromethods</i> , 2008 , 11-20	0.4	
157	A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008 , 325, 146-53	4.7	190
156	ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. <i>Journal of Molecular Neuroscience</i> , 2008 , 35, 127-41	3.3	60

155	VIP, from gene to behavior and back: summarizing my 25 years of research. <i>Journal of Molecular Neuroscience</i> , 2008 , 36, 115-24	3.3	27
154	In memory of our teacher, Dr. Akira Arimura. <i>Journal of Molecular Neuroscience</i> , 2008 , 36, 3-7	3.3	
153	Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability. <i>Journal of Peptide Science</i> , 2008 , 14, 321-8	2.1	20
152	The Design, Synthesis, and Biological Evaluation of VIP and VIP Analogs. <i>Neuromethods</i> , 2008 , 1-9	0.4	
151	Primary Cell Cultures and Cell Lines. <i>Neuromethods</i> , 2008 , 21-26	0.4	1
150	Looking for novel ways to treat the hallmarks of Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 1183-96	5.9	16
149	Activity-dependent neuroprotective protein: from gene to drug candidate 2007 , 114, 146-54		62
148	Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo. <i>Journal of Molecular Neuroscience</i> , 2007 , 33, 278-83	3.3	24
147	NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. <i>Current Alzheimer Research</i> , 2007 , 4, 507-9	3	61
146	NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. <i>Current Pharmaceutical Design</i> , 2007 , 13, 1091-8	3.3	43
145	Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer. <i>Current Pharmaceutical Design</i> , 2007 , 13, 1099-104	3.3	36
144	Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. <i>Journal of Biological Chemistry</i> , 2007 , 282, 34448-56	5.4	87
143	Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007 , 323, 438-49	4.7	157
142	Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. <i>Developmental Biology</i> , 2007 , 303, 814-24	3.1	110
141	Novel analogs of VIP with multiple C-terminal domains. <i>Peptides</i> , 2007 , 28, 1622-30	3.8	4
140	NAP protects hippocampal neurons against multiple toxins. <i>Peptides</i> , 2007 , 28, 2004-8	3.8	30
139	Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. <i>Journal of Molecular Neuroscience</i> , 2007 , 31, 165-70	3.3	119
138	Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. <i>Journal of Molecular Neuroscience</i> , 2007 , 31, 183-200	3.3	25

137	Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein. <i>Brain Research Reviews</i> , 2006 , 52, 107-18		39
136	Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate. <i>Current Alzheimer Research</i> , 2006 , 3, 197-9	3	24
135	NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 319, 332-9	4.7	36
134	Novel extended and branched N-terminal analogs of VIP. <i>Regulatory Peptides</i> , 2006 , 137, 42-9		7
133	VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new neuroprotection target. <i>Peptides</i> , 2006 , 27, 2867-76	3.8	28
132	Peptide neuroprotection through specific interaction with brain tubulin. <i>Journal of Neurochemistry</i> , 2006 , 98, 973-84	6	96
131	A splice variant to PACAP receptor that is involved in spermatogenesis is expressed in astrocytes. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1070, 484-90	6.5	7
130	NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1070, 500-6	6.5	31
129	Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. <i>Journal of Molecular Neuroscience</i> , 2006 , 28, 303-7	3.3	19
128	VIP-and PACAP-Related Neuroprotection 2006 , 1379-1384		
127	The influence of the peptide NAP on Mac-1-deficient mice following closed head injury. <i>Peptides</i> , 2005 , 26, 1520-7	3.8	22
126	Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina. <i>Peptides</i> , 2005 , 26, 2579-84	3.8	15
125	NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). <i>CNS Neuroscience & Therapeutics</i> , 2005 , 11, 353-68		108
124	Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. <i>Neuroscience Letters</i> , 2005 , 373, 73-8	3.3	38
123	Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding. <i>Journal of Molecular Neuroscience</i> , 2005 , 25, 215-24	3.3	6
122	Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. <i>Journal of Molecular Neuroscience</i> , 2005 , 25, 225-38	3.3	52
121	Summer Neuropeptide Conference: The 14th Annual Meeting of the Summer Neuropeptide Conference, Miami Beach, Florida, USA, July 5 th , 2004. <i>Neuropeptides</i> , 2005 , 39, 29-33	3.3	
120	The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro. <i>Investigative Ophthalmology and Visual Science</i> , 2005 , 46, 933-8		57

119	Neuroendocrine Aspects of the Molecular Chaperones ADNF and ADNP 2005 , 251-262		3
118	The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. <i>Current Alzheimer Research</i> , 2005 , 2, 149-53	3	47
117	PolyADP-ribosylation is involved in neurotrophic activity. <i>Journal of Neuroscience</i> , 2005 , 25, 7420-8	6.6	80
116	Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. <i>Neuron Glia Biology</i> , 2004 , 1, 193-9		79
115	Protective peptides that are orally active and mechanistically nonchiral. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 309, 1190-7	4.7	55
114	A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. <i>Journal of Biological Chemistry</i> , 2004 , 279, 28531-8	5.4	108
113	Neuropeptides 2003. <i>Journal of Molecular Neuroscience</i> , 2004 , 22, 1-2	3.3	
112	NAP mechanisms of neuroprotection. <i>Journal of Molecular Neuroscience</i> , 2004 , 24, 67-72	3.3	45
111	Brain injury-dependent expression of activity-dependent neuroprotective protein. <i>Journal of Molecular Neuroscience</i> , 2004 , 24, 181-7	3.3	28
110	Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2004 , 18, 623-40	6.5	17
109	Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. <i>Regulatory Peptides</i> , 2004 , 123, 33-41		73
108	Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. <i>Neuroscience Letters</i> , 2004 , 361, 128-31	3.3	71
107	The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. <i>Journal of Alzheimer's Disease</i> , 2004 , 6, S37-41	4.3	65
106	Injections of the neuroprotective peptide NAP to newborn mice attenuate head-injury-related dysfunction in adults. <i>NeuroReport</i> , 2003 , 14, 481-4	1.7	15
105	Antagonism of VIP-stimulated cyclic AMP formation in chick brain. <i>Journal of Molecular Neuroscience</i> , 2003 , 20, 163-72	3.3	9
104	From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. <i>Journal of Molecular Neuroscience</i> , 2003 , 20, 315-22	3.3	77
103	Complex array of cytokines released by vasoactive intestinal peptide. <i>Neuropeptides</i> , 2003 , 37, 111-9	3.3	51
102	Activity-dependent neuroprotective protein: a novel gene essential for brain formation. <i>Developmental Brain Research</i> , 2003 , 144, 83-90		164

101	The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. <i>Peptides</i> , 2003 , 24, 1413-23	3.8	73
100	VIP and drug design. <i>Current Pharmaceutical Design</i> , 2003 , 9, 483-94	3.3	37
99	Differential expression of embryonic and maternal activity-dependent neuroprotective protein during mouse development. <i>American Journal of Obstetrics and Gynecology</i> , 2002 , 187, 973-6	6.4	18
98	Peptides as drug candidates against Alzheimer's disease. <i>Drug Development Research</i> , 2002 , 56, 475-481	5.1	5
97	NAP accelerates the performance of normal rats in the water maze. <i>Journal of Molecular Neuroscience</i> , 2002 , 19, 167-70	3.3	32
96	Neuropeptides in the new millennium. <i>Journal of Molecular Neuroscience</i> , 2002 , 18, 1-4	3.3	1
95	(N-stearyl, norleucine ¹⁷)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist. <i>Journal of Molecular Neuroscience</i> , 2002 , 18, 29-35	3.3	21
94	A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene Atlas array analysis. <i>Journal of Molecular Neuroscience</i> , 2002 , 18, 37-43	3.3	26
93	NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. <i>Stroke</i> , 2002 , 33, 1085-92	6.7	106
92	A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes. <i>Life Sciences</i> , 2002 , 71, 2543-52	6.8	9
91	The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase. <i>Regulatory Peptides</i> , 2002 , 108, 175-7		7
90	In vitro and in vivo treatment of colon cancer by VIP antagonists. <i>Regulatory Peptides</i> , 2002 , 109, 127-33		20
89	A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines. <i>Cancer</i> , 2001 , 92, 2172-80	6.4	32
88	VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2001 , 68, 55-64	4.4	40
87	A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells. <i>Journal of Molecular Neuroscience</i> , 2001 , 17, 331-9	3.3	21
86	Cloning and characterization of the human activity-dependent neuroprotective protein. <i>Journal of Biological Chemistry</i> , 2001 , 276, 708-14	5.4	166
85	IGF-I as a mediator of VIP/activity-dependent neurotrophic factor-stimulated embryonic growth. <i>Endocrinology</i> , 2001 , 142, 3348-53	4.8	26
84	Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures. <i>Neuroscience Letters</i> , 2001 , 307, 167-70	3.3	34

83	Neuroprotective peptide drug delivery and development: potential new therapeutics. <i>Trends in Neurosciences</i> , 2001 , 24, 700-5	13.3	69
82	Intranasal Delivery of Bioactive Peptides or Peptide Analogues Enhances Spatial Memory and Protects Against Cholinergic Deficits 2001 , 363-370		1
81	VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. <i>Journal of Molecular Neuroscience</i> , 2000 , 15, 137-45	3.3	63
80	VIP-Related protection against Iodoacetate toxicity in pheochromocytoma (PC12) cells: a model for ischemic/hypoxic injury. <i>Journal of Molecular Neuroscience</i> , 2000 , 15, 147-54	3.3	51
79	CREB contributes to the increased neurite outgrowth of sensory neurons induced by vasoactive intestinal polypeptide and activity-dependent neurotrophic factor. <i>Brain Research</i> , 2000 , 868, 31-8	3.7	58
78	Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. <i>Brain Research</i> , 2000 , 854, 257-62	3.7	134
77	A new concept in the pharmacology of neuroprotection. <i>Journal of Molecular Neuroscience</i> , 2000 , 14, 61-8	3.3	71
76	Experimental intrauterine growth retardation alters renal development. <i>Pediatric Nephrology</i> , 2000 , 15, 192-5	3.2	102
75	Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway. <i>Journal of Neuroscience</i> , 2000 , 20, 3622-30	6.6	122
74	A glia-derived signal regulating neuronal differentiation. <i>Journal of Neuroscience</i> , 2000 , 20, 8012-20	6.6	190
73	A novel peptide prevents death in enriched neuronal cultures. <i>Regulatory Peptides</i> , 2000 , 96, 39-43		60
72	VIP and the potent analog, stearyl-Nle(17)-VIP, induce proliferation of keratinocytes. <i>FEBS Letters</i> , 2000 , 475, 78-83	3.8	34
71	VIP-derived sequences modified by N-terminal stearyl moiety induce cell death: the human keratinocyte as a model. <i>FEBS Letters</i> , 2000 , 475, 71-7	3.8	17
70	Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. <i>Journal of Neurochemistry</i> , 1999 , 72, 1283-93	6	283
69	Activity-dependent neurotrophic factor peptide (ADNF9) protects neurons against oxidative stress-induced death. <i>Journal of Neurochemistry</i> , 1999 , 73, 2341-7	6	52
68	Vasoactive intestinal peptide. Link between electrical activity and glia-mediated neurotrophism. <i>Annals of the New York Academy of Sciences</i> , 1999 , 897, 17-26	6.5	26
67	Vasoactive intestinal peptide regulates embryonic growth through the action of activity-dependent neurotrophic factor. <i>Annals of the New York Academy of Sciences</i> , 1999 , 897, 92-100	6.5	14
66	A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein. <i>Annals of the New York Academy of Sciences</i> , 1999 , 897, 125-35	6.5	48

65	Activity-dependent neurotrophic factor: a potent regulator of embryonic growth and development. <i>Anatomy and Embryology</i> , 1999 , 200, 65-71		23
64	Locomotor activity causes a rapid up-regulation of vasoactive intestinal peptide in the rat hippocampus. <i>Hippocampus</i> , 1999 , 9, 534-41	3.5	24
63	A femtomolar-acting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: a potential neuroprotective mechanism. <i>Neuroscience Letters</i> , 1999 , 264, 9-12	3.3	42
62	Vasoactive intestinal peptide inhibits cytokine production in T lymphocytes through cAMP-dependent and cAMP-independent mechanisms. <i>Regulatory Peptides</i> , 1999 , 84, 55-67		24
61	SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival. <i>Peptides</i> , 1999 , 20, 629-33	3.8	22
60	Protection against developmental deficiencies by a lipophilic VIP analogue. <i>Neurochemical Research</i> , 1998 , 23, 689-93	4.6	12
59	In memory of Victor Mutt. Discoveries of biologically important peptides. <i>Journal of Molecular Neuroscience</i> , 1998 , 11, 105-8	3.3	1
58	Stress genes in the nervous system during development and aging diseases. <i>Annals of the New York Academy of Sciences</i> , 1998 , 851, 123-8	6.5	9
57	VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide. <i>Annals of the New York Academy of Sciences</i> , 1998 , 865, 207-12	6.5	35
56	Multiple actions of a hybrid PACAP antagonist: neuronal cell killing and inhibition of sperm motility. <i>Annals of the New York Academy of Sciences</i> , 1998 , 865, 266-73	6.5	9
55	The identification of secreted heat shock 60-like protein from rat glial cells and a human neuroblastoma cell line. <i>Neuroscience Letters</i> , 1998 , 250, 37-40	3.3	48
54	Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun. <i>Journal of Biological Chemistry</i> , 1998 , 273, 31427-36	5.4	138
53	Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis. <i>Journal of Neurochemistry</i> , 1998 , 70, 2165-73	6	45
52	Neurobehavioral development of neonatal mice following blockade of VIP during the early embryonic period. <i>Peptides</i> , 1997 , 18, 1131-7	3.8	44
51	Identity of neurotrophic molecules released from astroglia by vasoactive intestinal peptide. <i>Annals of the New York Academy of Sciences</i> , 1997 , 814, 167-73	6.5	41
50	Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity. <i>Developmental Brain Research</i> , 1997 , 99, 167-75		46
49	Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides. <i>Journal of Molecular Neuroscience</i> , 1997 , 9, 211-22	3.3	70
48	Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. <i>Journal of Neurobiology</i> , 1997 , 33, 329-42		54

47	Vasoactive intestinal peptide releases interleukin-1 from astrocytes. <i>Annals of the New York Academy of Sciences</i> , 1996 , 805, 280-7; discussion 287-9	6.5	4
46	Regulation of VIP gene expression in general. Human lung cancer cells in particular. <i>Journal of Molecular Neuroscience</i> , 1996 , 7, 99-110	3.3	17
45	Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin?. <i>Journal of Molecular Neuroscience</i> , 1996 , 7, 235-44	3.3	60
44	A VIP hybrid antagonist: from developmental neurobiology to clinical applications. <i>Cellular and Molecular Neurobiology</i> , 1995 , 15, 675-87	4.6	19
43	Blockade of VIP during neonatal development induces neuronal damage and increases VIP and VIP receptors in brain. <i>Annals of the New York Academy of Sciences</i> , 1994 , 739, 211-25	6.5	28
42	Neuropeptide regulation of mitosis. <i>Annals of the New York Academy of Sciences</i> , 1994 , 739, 253-61	6.5	9
41	PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP)/VASOACTIVE INTESTINAL PEPTIDE (VIP) RECEPTOR SUBTYPES IN RAT TISSUES: INVESTIGATION OF RECEPTOR BINDING, A NOVEL VIP RECEPTOR ANTAGONIST AND CHEMICAL CROSS-LINKING . <i>Biomedical Research</i> , 1994 , 15, 145-153	1.5	3
40	Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. <i>Nature</i> , 1993 , 362, 155-8	50.4	244
39	Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene. <i>Journal of Molecular Neuroscience</i> , 1993 , 4, 185-93	3.3	50
38	Neuropeptides as growth and differentiation factors in general and VIP in particular. <i>Journal of Molecular Neuroscience</i> , 1993 , 4, 1-9	3.3	58
37	Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. <i>Brain Research</i> , 1992 , 570, 49-53	3.7	138
36	Cytokine regulation of neuronal survival. <i>Journal of Neurochemistry</i> , 1992 , 58, 454-60	6	187
35	Spontaneous electrical activity regulates vasoactive intestinal peptide expression in dissociated spinal cord cell cultures. <i>Molecular Brain Research</i> , 1991 , 10, 235-40		40
34	A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes. <i>Brain Research</i> , 1991 , 540, 319-21	3.7	58
33	Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. <i>Peptides</i> , 1991 , 12, 187-92	3.8	75
32	The complete structure of the rat VIP gene. <i>Molecular Brain Research</i> , 1990 , 7, 261-7		42
31	Lactation elevates vasoactive intestinal peptide messenger ribonucleic acid in rat suprachiasmatic nucleus. <i>Endocrinology</i> , 1989 , 124, 181-6	4.8	35
30	Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist. <i>Endocrinology</i> , 1989 , 125, 2945-9	4.8	98

29	VIP: molecular biology and neurobiological function. <i>Molecular Neurobiology</i> , 1989 , 3, 201-36	6.2	214
28	Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus. <i>Journal of Molecular Neuroscience</i> , 1989 , 1, 55-61	3.3	16
27	Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus. <i>Journal of Molecular Neuroscience</i> , 1989 , 1, 55-61	3.3	31
26	VIP-mRNA is increased in hypertensive rats. <i>Brain Research</i> , 1989 , 503, 304-7	3.7	33
25	Hormonal regulation of somatostatin messenger RNA. <i>Synapse</i> , 1988 , 2, 317-25	2.4	33
24	Localization of vasopressin-, vasoactive intestinal polypeptide-, peptide histidine isoleucine- and somatostatin-mRNA in rat suprachiasmatic nucleus. <i>Cell and Tissue Research</i> , 1988 , 252, 307-15	4.2	104
23	Biosynthesis and regulation of expression. The vasoactive intestinal peptide gene. <i>Annals of the New York Academy of Sciences</i> , 1988 , 527, 77-87	6.5	8
22	Vasoactive intestinal peptide gene expression from embryos to aging rats. <i>Neuroendocrinology</i> , 1988 , 47, 27-31	5.6	59
21	The survival of dentate gyrus neurons in dissociated culture. <i>Developmental Brain Research</i> , 1987 , 433, 199-218		27
20	Developmental expression of the VIP-gene in brain and intestine. <i>Molecular Brain Research</i> , 1987 , 2, 137-148		69
19	Developmental expression of the VIP-gene in brain and intestine. <i>Brain Research</i> , 1987 , 388, 137-48	3.7	23
18	The gene encoding vasoactive intestinal peptide is located on human chromosome 6p21---6qter. <i>Human Genetics</i> , 1987 , 75, 41-4	6.3	18
17	Hypothalamic vasoactive intestinal peptide messenger ribonucleic acid is increased in lactating rats. <i>Endocrinology</i> , 1986 , 119, 2497-501	4.8	31
16	Detection of vasoactive intestinal peptide-encoding messenger ribonucleic acid in the rat ovaries. <i>Endocrinology</i> , 1986 , 119, 2606-10	4.8	38
15	High levels of vasoactive intestinal peptide in human milk. <i>Biochemical and Biophysical Research Communications</i> , 1985 , 133, 228-32	3.4	42
14	Detection of mRNAs containing regulatory peptide coding sequences using synthetic oligodeoxynucleotides. <i>Journal of Cellular Biochemistry</i> , 1984 , 26, 147-56	4.7	23
13	Studies toward the biosynthesis of vasoactive intestinal peptide (VIP). <i>Peptides</i> , 1984 , 5, 161-6	3.8	22
12	A possible high molecular weight precursor to vasoactive intestinal polypeptide sequestered into pheochromocytoma chromaffin granules. <i>Regulatory Peptides</i> , 1983 , 6, 111-9		15

11	Monoclonal antibodies against vasoactive intestinal polypeptide: studies of structure and related antigens. <i>Journal of Neurochemistry</i> , 1983 , 41, 549-55	6	19
10	Conditioned media from activated lymphocytes maintain sympathetic neurons in culture. <i>Developmental Brain Research</i> , 1982 , 282, 93-7		19
9	Multiple tubulin forms are expressed by a single neurone. <i>Nature</i> , 1981 , 294, 477-80	50.4	123
8	Protein synthesis in rat brain microvessels decreases with aging. <i>Journal of Neurochemistry</i> , 1981 , 36, 1311-5	6	16
7	The characterization and phosphorylation of an actin-like protein in synaptosomal membranes. <i>Biochimica Et Biophysica Acta (BBA) - Protein Structure</i> , 1980 , 624, 153-62		16
6	Tubulin: an integral protein of mammalian synaptic vesicle membranes. <i>Journal of Neurochemistry</i> , 1980 , 34, 26-32	6	147
5	Translation in vitro of rat brain mRNA coding for a variety of tubulin forms. <i>FEBS Journal</i> , 1980 , 103, 13-20		57
4	The alpha-subunit of tubulin is preferentially associated with brain presynaptic membranes. <i>FEBS Letters</i> , 1979 , 99, 86-90	3.8	66
3	Tubulin microheterogeneity in neuroblastoma and glioma cell lines differs from that of the brain. <i>Brain Research</i> , 1979 , 171, 171-5	3.7	43
2	Tubulin microheterogeneity increases with rat brain maturation. <i>Nature</i> , 1978 , 276, 411-3	50.4	220
1	Identification of tubulin associated with rat brain myelin. <i>FEBS Letters</i> , 1978 , 95, 169-72	3.8	38